Get started

PHARMA

Olema Pharmaceuticals: Enjoy!Olema is currently developing a "cancer" drug that suppresses the body's production of Estrogen. Now this could be useful for breast cancer treatment but the real target audience, in my opinion, is hormone replacement therapy for gender transition. I don't necessarily endorse this kind of product but given the corporate and governmental policies surrounding the issue, I believe it could definitely be a very good financial opportunity. I charted this about a month ago and it has moved even more aggressively than I expected. This could be because this type of product, I imagine, would have to be developed under the current administration. Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of targeted therapies for women's cancers. It also focuses on developing therapies for the treatment of breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA. The listed name for OLMA is Olema Pharmaceuticals, Inc. Common Stock
NASDAQ:OLMALong
by Goontata84
MGRX Biotechonolgy IPO LONGMGRX a recent IPO produces a med for erectile dysfunction without FDA approval; They are basically selling a generic version of an approved medication and bypassing the patent protections and betting they will fly under the regulator radar apparatus. As might be expeted this recent nano-IPO is highlly volatile. Play with it only if you have the requisite skills to do so and only with risk capital. it does the marketing through direct to consumer telehealth services. >>>>>>>>>>>>>>>>>>See also the link below <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<< On review and analysis on the 30 minute chart, the price action is squeezing down in a flat bottom triangle likely setting up a breakout upside. The RSI oscillator shows RSI crossing 50% from below. Volatility is compressing down inside the triangle for a squeeze set up. Targets are based on the supply and demand zones of the Luxalgo indicator. The first parget is the midline between the zones while the final target is just below the supply zone. As can be seen on the chart, the first target is about 100% upside while the final target is 200% upside. One of the position is closed at each target making the return 150% overall. Stop loss is below the demand zone. A stop loss is 15% yields an overall reward to risk ration of 10:1.
NASDAQ:MGRXLong
by AwesomeAvani
ELOX 1.79M Float VOL Kicking in NOW Looks like a Cloud Pop ELOX with its 1.79M float and volume coming in to turn it about 1 time today unless the volume kicks in....Which is still enough to make this move. Good push down to start the day got in at $3.50 Probably if things stay the way they are now then it could go for !.00 from here. Looking for spikes to volume to catch fomo. As I am typing this volume is dragging and looks like its going to hit about 780k for the day. I would say that if you see the volume spike to about 6k a min then we could have a repeat of yesterday. This chart formation here on the 2 min looks like a setup for a dip into liquidity then a possible fomo trigger to break yesterdays high. *In the last 3 mins !5k Volume has come through That puts us really close to the 6k a min needed. Stay tuned I think this kicks in overdrive in about 15 -30 mins by iCantw84it 01/06/23
ELong
by iCantw84it
1
Sanofi found support at previous resistance.Sanofi - 30d expiry - We look to Buy a break of 88.01 (stop at 84.48) Previous resistance level of 88 broken. Our short term bias remains positive. Previous resistance, now becomes support at 88. 50 1day EMA is at 86.97. Support is located at 88 and should stem dips to this area. Daily signals are mildly bullish. Our profit targets will be 96.72 and 97.72 Resistance: 91.00 / 92.90 / 95.00 Support: 90.00 / 88.00 / 86.20 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
EURONEXT:SANLong
by Saxo
EYPT | Short term bottom? | LONGEyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
NASDAQ:EYPTLong
by DivergenceSeeker
APOLLOHOSP is ready to breakout triangle patternNSE:APOLLOHOSP large cap health care stock is touching triangle's resistance for 5th time in this year. With positive earnings and bull market, this breakout can sustain if pharma sector picks momentum again. Key note : Always follow proper risk management to avoid losing capital from false breakouts as this is common. Caution : This is a knowledge sharing analysis, not a call. Profits are not made from following ideas, but by following Risk Management .
NSE:APOLLOHOSP
by samplespaz
1